[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![stock_logging Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1935417778166439936.png) Stock.Logging [@stock_logging](/creator/twitter/stock_logging) on x XXX followers
Created: 2025-07-17 09:00:25 UTC

$CAMX.ST $CAMX
Strong quarterly results from Camurus (part of my biotech basket):

➡️ Revenue: SEK 675.5m, +51.8% YoY (vs. SEK 653m est.)
➡️ Operating profit: SEK 292.05m (43.2% margin), +253.5% YoY
➡️ EPS: SEK 4.08, +226.4% YoY (vs. SEK XXXX est.)

Unchallenged market leader in opioid addiction treatment, strong pipeline, resubmission for CAM2029 (acromegaly treatment) in the U.S. expected in Q3/25, a recently announced long-term collaboration with Eli Lilly ($LLY) on its proprietary FluidCrystal technology, incredible operating leverage – lots to like here. In my view, one of the best high-growth stocks in Europe.

Current valuation not cheap though:
➡️ Forward P/E 2025: XX
➡️ Forward P/E 2026: XX
➡️ Forward P/E 2027: XX

![](https://pbs.twimg.com/media/GwC8ph8XUAE9SuO.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945770553790411061/c:line.svg)

**Related Topics**
[$camx](/topic/$camx)
[$camxst](/topic/$camxst)

[Post Link](https://x.com/stock_logging/status/1945770553790411061)